Selank vs SS-31
Updated July 29, 2026 · Reviewed by the PeptidesDB Editorial team
A data-driven comparison of Selank and SS-31 (also searched as SS-31 vs Selank) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.
Verdict
Selank centers on neuro, while SS-31 leans toward inflammation. On indexed research, SS-31 is ahead (Selank: 6 studies, Human evidence; SS-31: 19, Human evidence). Choose by goal — and read the primary studies. This is research information, not medical advice.
Key takeaways
- •Selank is strongest for neuro; SS-31 for inflammation.
- •Evidence: Selank Human evidence (6 studies) vs SS-31 Human evidence (19).
- •Both are research-use compounds — not FDA-approved.
Effect profiles, overlaid
At a glance
Selank vs SS-31: side-by-side
| Metric | Selank | SS-31 |
|---|---|---|
| Class | Cognitive | Longevity |
| Regulatory status | Research use only | Research use only |
| Evidence grade | Human evidence | Human evidence |
| Studies indexed | 6 | 19 |
| Research level | Well Studied | Well Studied |
| Strongest effect | Neuro & mood | Inflammation & immune |
| Healing & recovery | 0.0 | 3.0▲ |
| Muscle & body comp | 0.0 | 2.0▲ |
| Metabolic & appetite | 0.0 | 4.0▲ |
| Neuro & mood | 4.0▲ | 3.0 |
| Sleep & circadian | 1.0▲ | 1.0▲ |
| Inflammation & immune | 1.0 | 4.0▲ |
| Skin & aesthetics | 0.0 | 0.0 |
▲ marks the higher AI-assigned effect score (0–5, describing where the literature concentrates — not clinical efficacy).
Mechanism & pharmacokinetics
| Property | Selank | SS-31 |
|---|---|---|
| Mechanism | Anxiolytic heptapeptide (Tuftsin analog) | Targets inner mitochondrial membrane to enhance function and reduce ROS |
| Route | Intranasal / subcutaneous (research use) | Subcutaneous injection |
Established pharmacology — curated for well-characterized compounds and AI-summarized otherwise. A blank (—) means no reliable single value is published (half-life figures for some peptides genuinely disagree across sources). Verify against primary sources such as FDA labels and ClinicalTrials.gov.
What is Selank?
### Selank Summary Selank is a synthetic peptide derived from the naturally occurring peptide tuftsin, primarily studied for its potential anxiolytic and cognitive-enhancing properties. Research into Selank has focused on its effects on neuroprotection, stress response, and cognitive function, although further studies are needed to fully understand its mechanisms and therapeutic applications.
Full Selank profile, mechanism & studies →What is SS-31?
### Summary SS-31, also known as Elamipretide, is a peptide that has garnered attention for its potential role in mitochondrial protection and its implications in various health conditions, particularly those involving oxidative stress and mitochondrial dysfunction.
Full SS-31 profile, mechanism & studies →Which is better for your goal?
| Goal | Better fit | Why |
|---|---|---|
| Healing | SS-31 | 3.0/5 effect signal |
| Muscle | SS-31 | 2.0/5 effect signal |
| Metabolic | SS-31 | 4.0/5 effect signal |
| Neuro | Selank | 4.0/5 effect signal |
| Sleep | Even | Both ~1.0/5 |
| Inflammation | SS-31 | 4.0/5 effect signal |
Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.
Can you stack Selank and SS-31?
People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because neither compound is FDA-approved, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.
Selank vs SS-31: side effects
No community-reported effects logged yet.
No community-reported effects logged yet.
Anonymous community reports (count = number of reports), not clinical incidence rates.
What the research says
Selank has 6 approved studies indexed (Human evidence), and SS-31 has 19 (Human evidence). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.
Frequently asked questions
Is Selank or SS-31 better?
It depends on your goal. Selank is strongest for neuro; SS-31 for inflammation. SS-31 has more indexed studies (19). See the goal-by-goal breakdown above.
Is Selank or SS-31 better for weight loss?
SS-31 shows the stronger metabolic & appetite profile (4.0/5) in the AI-assigned effect profile — though weight-loss outcomes depend on the individual and the evidence base.
Is Selank or SS-31 better for muscle?
SS-31 leads on the muscle & body-composition axis (2.0/5).
Which has more research, Selank or SS-31?
Selank has 6 approved studies indexed (Human evidence); SS-31 has 19 (Human evidence). Higher counts mean more to read, not proven superiority.
Can you stack Selank and SS-31?
Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.
What are the side effects of Selank vs SS-31?
Selank: no community-reported effects logged yet. SS-31: none logged yet. These are anonymous reports, not incidence rates — see each profile.
Is Selank or SS-31 FDA-approved?
Selank is a research-use compound and is not FDA-approved. SS-31 is not FDA-approved. Research-use status is not a legal clearance to compound or use in humans.
Is SS-31 better than Selank?
For inflammation, SS-31 has the edge; for neuro, Selank does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.
Comparing related peptides
Regulatory & legal status
Selank and SS-31 are research-use compounds and are not FDA-approved for human use. FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed July 29, 2026.